The Pennant Group (PNTG) Stock Price, News & Analysis

Company Overview

The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support. The company operates home health, hospice, and home care agencies, as well as senior living communities throughout Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.

Key Stats

• Today's Range: $30.75 to $31.57
• 50-Day Range: $30.50 to $35.70
• 52-Week Range: $13.24 to $37.13
• Volume: 128,903 shs
• Average Volume: 200,685 shs
• Market Capitalization: $1.06 billion
• P/E Ratio: 45.57
• Dividend Yield: N/A
• Price Target: $38.25
• Consensus Rating: Moderate Buy

The Pennant Group Stock Analysis - MarketRank™

The Pennant Group scored higher than 74% of companies evaluated by MarketBeat, and ranked 322nd out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

The Pennant Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

The Pennant Group has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 21.33%

Earnings Growth

Earnings for The Pennant Group are expected to grow by 21.33% in the coming year, from $0.75 to $0.91 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of The Pennant Group is 45.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.45.

Price to Earnings Ratio vs. Sector

The P/E ratio of The Pennant Group is 45.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 100.40.

Price to Earnings Growth Ratio

The Pennant Group has a PEG Ratio of 3.22. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

The Pennant Group has a P/B Ratio of 6.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.26% of the outstanding shares of The Pennant Group have been sold short.

Short Interest Ratio / Days to Cover

The Pennant Group has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in The Pennant Group has recently increased by 17.05%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

The Pennant Group does not currently pay a dividend.

Dividend Growth

The Pennant Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.26% of the outstanding shares of The Pennant Group have been sold short.

Short Interest Ratio / Days to Cover

The Pennant Group has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in The Pennant Group has recently increased by 17.05%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.30

News Sentiment

The Pennant Group has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for The Pennant Group this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for PNTG on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added The Pennant Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, The Pennant Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,753.00 in company stock.

Percentage Held by Insiders

Only 5.80% of the stock of The Pennant Group is held by insiders.

Percentage Held by Institutions

85.88% of the stock of The Pennant Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PNTG Stock Analysis - Frequently Asked Questions

How have PNTG shares performed this year?

The Pennant Group's stock was trading at $13.92 at the beginning of 2024. Since then, PNTG stock has increased by 122.6% and is now trading at $30.99.
View the best growth stocks for 2024 here.

How were The Pennant Group's earnings last quarter?

The Pennant Group, Inc. (NASDAQ:PNTG) posted its quarterly earnings data on Wednesday, February, 28th. The company reported $0.18 earnings per share for the quarter, missing the consensus estimate of $0.19 by $0.01. The firm had revenue of $145.95 million for the quarter, compared to analyst estimates of $136.79 million. The Pennant Group had a trailing twelve-month return on equity of 13.47% and a net margin of 3.24%.

Who are The Pennant Group's major shareholders?

The Pennant Group's top institutional shareholders include FMR LLC (7.36%), Wasatch Advisors LP (3.05%), Crewe Advisors LLC (2.16%) and Geode Capital Management LLC (1.99%). Insiders that own company stock include John G Nackel, Brent Guerisoli, John J Gochnour, Barry M Smith, Jennifer Freeman and Joanne Stringfield.
View institutional ownership trends.

How do I buy shares of The Pennant Group?

Shares of PNTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of The Pennant Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that The Pennant Group investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), ServiceNow (NOW), Palo Alto Networks (PANW) and Adobe (ADBE).

Company Calendar

• Last Earnings: 2/28/2024
• Today: 12/03/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/26/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Health services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:PNTG
• CUSIP: N/A
• CIK: 1766400
• Web: www.pennantgroup.com
• Phone: 208-506-6100
• Fax: N/A
• Employees: 5,791
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $38.25
• High Stock Price Target: $40.00
• Low Stock Price Target: $37.00
• Potential Upside/Downside: +23.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.68
• Trailing P/E Ratio: 45.57
• Forward P/E Ratio: 41.32
• P/E Growth: 3.22
• Net Income: $13.38 million
• Net Margins: 3.24%
• Pretax Margin: 4.46%
• Return on Equity: 13.47%
• Return on Assets: 3.81%

Debt

• Debt-to-Equity Ratio: 0.58
• Current Ratio: 1.12
• Quick Ratio: 1.12

Sales & Book Value

• Annual Sales: $544.89 million
• Price / Sales: 1.95
• Cash Flow: $0.77 per share
• Price / Cash Flow: 40.33
• Book Value: $4.86 per share
• Price / Book: 6.38

Miscellaneous

• Outstanding Shares: 34,350,000
• Free Float: 32,356,000
• Market Cap: $1.06 billion
• Optionable: Optionable
• Beta: 1.95